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Summary
Background Standard-of-care antiretroviral therapy (ART) uses a combination of drugs deemed essential to minimise 
treatment failure and drug resistance. Protease inhibitors are potent, with a high genetic barrier to resistance, and 
have potential use as monotherapy after viral load suppression is achieved with combination treatment. We aimed to 
assess clinical risks and beneﬁ ts of protease inhibitor monotherapy in long-term clinical use: in particular, the eﬀ ect 
on drug resistance and future treatment options.
Methods In this pragmatic, parallel-group, randomised, controlled, open-label, non-inferiority trial, we enrolled 
adults (≥18 years of age) positive for HIV attending 43 public sector treatment centres in the UK who had suppressed 
viral load (<50 copies per mL) for at least 24 weeks on combination ART with no change in the previous 12 weeks and 
a CD4 count of more than 100 cells per μL. Participants were randomly allocated (1:1) to maintain ongoing triple 
therapy (OT) or to switch to a strategy of physician-selected ritonavir-boosted protease inhibitor monotherapy 
(PI-mono); we recommended ritonavir (100 mg)-boosted darunavir (800 mg) once daily or ritonavir (100 mg)-boosted 
lopinavir (400 mg) twice daily, with prompt return to combination treatment if viral load rebounded. All treatments 
were oral. Randomisation was with permuted blocks of varying size and stratiﬁ ed by centre and baseline ART; we 
used a computer-generated, sequentially numbered randomisation list. The primary outcome was loss of future drug 
options, deﬁ ned as new intermediate-level or high-level resistance to one or more drugs to which the patient’s virus 
was deemed sensitive at trial entry (assessed at 3 years; non-inferiority margin of 10%). We estimated probability of 
rebound and resistance with Kaplan-Meier analysis. Analyses were by intention to treat. This trial is registered with 
the International Standard Randomised Controlled Trial Number registry, number ISRCTN04857074.
Findings Between Nov 4, 2008, and July 28, 2010, we randomly allocated 587 participants to OT (291) or PI-mono 
(296). At 3 years, one or more future drug options had been lost in two participants (Kaplan-Meier estimate 0·7%) 
in the OT group and six (2·1%) in the PI-mono group: diﬀ erence 1·4% (–0·4 to 3·4); non-inferiority shown. 
49 (16·8%) participants in the OT group and 65 (22·0%) in the PI-mono group had grade 3 or 4 clinical adverse 
events (diﬀ erence 5·1% [95% CI –1·3 to 11·5]; p=0·12); 45 (six treatment related) and 56 (three treatment related) 
had serious adverse events.
Interpretation Protease inhibitor monotherapy, with regular viral load monitoring and prompt reintroduction of 
combination treatment for rebound, preserved future treatment options and did not change overall clinical outcomes or 
frequency of toxic eﬀ ects. Protease inhibitor monotherapy is an acceptable alternative for long-term clinical management 
of HIV infection.
Funding National Institute for Health Research.
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Introduction
Current HIV treatment guidelines recommend a 
combination of two drug classes for initiation and 
maintenance of antiretroviral therapy (ART).1,2 The 
principle of combining drugs with diﬀ erent mechanisms 
of action to increase potency and reduce selection of 
drug-resistant mutants is common to the treatment of 
many infectious diseases. However, in HIV, the need for 
combination treatment might decrease once viral load 
has been suppressed.
Protease inhibitors are potent, with a high genetic 
barrier to resistance, and are the only drugs that act at 
many steps of the HIV lifecycle, thus having potential for 
use alone as monotherapy.3 Protease inhibitor mono-
therapy could be an attractive therapeutic option because 
of its potential to reduce renal, CNS, and other toxic 
eﬀ ects associated with drugs widely used in standard 
ART combinations. The high genetic barrier to resistance 
might reduce the risk of resistance during periods of 
suboptimum treatment adherence. Furthermore, use of 
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a single drug might decrease treatment costs. Although 
inadequate for initial treatment,4 ﬁ ndings from previous 
randomised trials of maintenance protease inhibitor 
monotherapy5–9 have shown high levels of short-term 
viral load suppression. However, these trials have not 
been of suﬃ  cient size and duration to address deﬁ nitively 
the eﬀ ects on long-term drug resistance, clinical disease 
progression, and drug toxic eﬀ ects in clinical practice.5–9 
Furthermore, investigators have mostly restricted the 
standard-of-care treatment to a speciﬁ c protease inhibitor 
regimen and mandated use of a particular protease 
inhibitor for monotherapy, neither of which takes 
account of the diversity of regimen selection in routine 
clinical practice.
We did a pragmatic randomised controlled trial com-
paring a protease inhibitor monotherapy treatment 
strategy with clinician-selected standard combination 
treatment, aiming to assess eﬀ ects on drug resistance, 
future treatment options, and other, long-term, clinically 
relevant outcomes.
Methods
Study design and patients
In this pragmatic, parallel-group, randomised, controlled, 
open-label, non-inferiority trial, we enrolled participants 
attending 43 public sector hospital-based HIV treatment 
centres in the UK. Eligible participants were adults aged 
18 years or older who were HIV positive, had been on ART 
consisting of two nucleoside reverse transcriptase inhibi-
tors (NRTIs) and one non-NRTI (NNRTI) or protease 
inhibitor for at least 24 weeks with no change in the 
previous 12 weeks, had a viral load of less than 50 copies 
per mL at screening and for at least 24 weeks before 
screening (one blip to less than 200 copies per mL allowed 
during this period if followed by at least two results less 
than 50 copies per mL), had a CD4 count of more than 
100 cells per μL at screening, and who were willing 
to continue current ART or change according to the 
randomised allocation. Exclusion criteria were known 
major protease inhibitor resistance mutations at previous 
resistance testing (if done; not mandated), previous ART 
change for unsatisfactory virological response (ie, slow 
initial virological suppression, incomplete suppression, 
or rebound; change for convenience or toxic eﬀ ect 
prevention or management allowed), protease inhibitor 
allergy, concomitant drugs with protease inhibitor 
interactions, present or anticipated need for radio therapy 
or cytotoxic chemotherapy, treatment for acute oppor-
tunistic infection within the previous 3 months, present 
or planned pregnancy, active substance misuse or 
psychiatric illness, history of HIV encephalopathy with a 
present deﬁ cit of more than 1 in any domain of the 
Research in context
Evidence before this study
We searched PubMed for reports published between 
Jan 1, 1998, and Jan 1, 2008, with no language restrictions, 
using terms including “protease inhibitors”, ”monotherapy”, 
and the individual drug names, and reviewed relevant HIV 
conference abstracts to identify randomised controlled trials 
that compared prote ase inhibitor monotherapy with triple 
antiretroviral therapy (ART) in patients who had previously 
achieved viral load suppression. We identiﬁ ed three trials, all 
investigating lopinavir monotherapy, and, overall, these trials 
supported the hypothesis of virological non-inferiority of 
monotherapy to triple therapy. Since then, authors of a 
meta-analysis of ten trials noted an overall risk ratio of 0·94 for 
viral load suppression at 48 weeks with protease inhibitor 
monotherapy compared with triple ART, with, at most, a 13% 
increase in the absolute risk of virological failure with protease 
inhibitor monotherapy.
Added value of this study
To our knowledge, this trial is the largest and longest-duration 
protease inhibitor monotherapy trial done so far, with more 
than three times the randomly allocated person follow-up time 
of previous trials, and thus it provides more precise estimates of 
important but uncommon eﬃ  cacy and safety outcomes than 
did previous trials. By contrast with previous studies that 
restricted the choice of drugs in both the monotherapy (single 
speciﬁ ed protease inhibitor) and combination ART (usually to a 
protease-inhibitor-containing combination, and with the same 
protease inhibitor as speciﬁ ed for monotherapy) groups, this 
trial used a pragmatic design representative of routine clinical 
care, with ﬂ exibility of drug selection in both treatment groups. 
Also, whereas previous trials compared predeﬁ ned regimens 
with short-term viral load endpoints, this trial compared 
treatment strategies with a primary eﬃ  cacy endpoint 
(preservation of drug options) relevant to long-term clinical 
management. In this trial we noted an increase of about 32% in 
absolute risk of virological failure with protease inhibitor 
monotherapy (much greater than that previously reported), but 
all patients with rebound resuppressed spontaneously or with 
reintroduction of combination ART. Findings from this trial 
showed that the protease inhibitor monotherapy strategy was 
non-inferior to triple ART in preservation of future treatment 
options and did not change overall clinical outcomes or 
frequency of toxic eﬀ ects.
Implications of all the available evidence
Protease inhibitor monotherapy does not increase the risk of 
drug resistance and is an acceptable alternative for long-term 
clinical management of HIV infection. Clinical beneﬁ ts, if any, 
seem slight, and some patients might need to switch back to 
combination ART. Nevertheless, this approach could appeal to 
patients who are stable on treatment but who wish to 
minimise their exposure to speciﬁ c drugs or more than one 
drug class.
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Neuropsychiatric AIDS Rating Scale,10,11 history of 
cardiovascular disease or a 10 year absolute coronary heart 
disease risk of more than 30% or more than 20% with 
diabetes or a family history of premature ischaemic heart 
disease or stroke,12 insulin-dependent diabetes mellitus, 
active or planned hepatitis C virus treatment, hepatitis B 
surface antigen positive at screening or since HIV 
diagnosis (unless hepatitis B DNA of less than 1000 copies 
per mL taken while oﬀ  drugs active against hepatitis B), or 
a fasting plasma glucose of more than 7·0 mmol/L 
at screening.
The protocol was approved by the Cambridgeshire 
4 Research Ethics Committee and Medicines and 
Healthcare Products Regulatory Agency. All participants 
provided written informed consent.
Randomisation and masking
Participants were randomly assigned (1:1) to maintain 
ongoing triple therapy (OT) or switch to a protease 
inhibitor monotherapy strategy (PI-mono). Randomisation 
was stratiﬁ ed by centre (nine groups, based on the 
eight largest sites and one group for the remaining sites) 
and baseline ART regimen (protease inhibitor or NNRTI). 
The computer-generated, sequentially numbered random-
isation list (random permuted blocks of varying size) was 
preprepared by WS. Sites faxed screening forms to the 
trial coordinating centre, where trial staﬀ  conﬁ rmed 
eligibility and did the randomisation (they could access 
the next number on the list, but not the whole list). 
Treatment allocation was open label. 
Procedures
In the OT group, we managed patients using triple 
combination treatment. In the PI-mono group, we 
switched patients to a single ritonavir-boosted protease 
inhibitor selected by the physician: we recommended 
darunavir (800 mg) boosted with ritonavir (100 mg) once 
daily or lopinavir (400 mg) boosted with ritonavir (100 mg) 
twice daily. Drugs were taken orally. Patients switching 
from NNRTI-based regimens continued NRTIs for the 
ﬁ rst 2 weeks. Protease inhibitor substitution was allowed 
in the event of toxic eﬀ ects or for convenience. The 
strategy required prompt reintroduction of NRTIs (switch 
of protease inhibitor to NNRTI optional) for protocol-
deﬁ ned conﬁ rmed viral load rebound and management 
with combination treatment for the remainder of the trial 
(subsequent switches for toxic eﬀ ects, convenience, and 
viral load failure allowed, as in OT group).
Study visits at baseline, weeks 4 and 8 (PI-mono 
group only), week 12, and every 12 weeks thereafter 
included assessment of clinical status, drug adherence 
(standardised questions), viral load, CD4 cell count, and 
safety blood tests (measured at site laboratory). Visits at 
baseline, week 12, week 48, and every 48 weeks thereafter 
included additional assessments of cardiovascular 
disease risk (Framingham equation),13 neurocognitive 
function (standard ﬁ ve-test battery),14,15 symptomatic 
peripheral neuropathy (Brief Peripheral Neuropathy 
Screen),16 and quality of life (self-completed Medical 
Outcomes Study HIV Health Survey question naire17,18). 
We classiﬁ ed clinical and laboratory events with protocol-
deﬁ ned diagnostic criteria (on the basis of Centers for 
Disease Control and Prevention criteria for AIDS,19 
INSIGHT criteria for serious non-AIDS events,20 and 
Division of AIDS criteria for adverse events21), and an 
independent physician at the coordinating centre 
reviewed them. We calculated estimated glomerular 
ﬁ ltration rate (eGFR) with the Chronic Kidney Disease 
Epidemiology Collaboration equation.22
If viral load was detectable at 50 copies per mL or 
higher at any visit, we repeated the test (on the same 
sample if available or a fresh sample draw if not). If viral 
load was less than 50 copies per mL on the repeat test, we 
continued routine follow-up, but if higher, we did 
adherence counselling and patients returned for a 
conﬁ rmatory test at least 4 weeks from the date that the 
ﬁ rst sample was taken. If viral load was less than 
50 copies per mL with the conﬁ rmatory test, we resumed 
Figure 1: Trial proﬁ le
ART=antiretroviral therapy. PI=protease inhibitor. NNRTI=non-nucleoside reverse transcriptase inhibitor. 
NRTI=nucleoside reverse transcriptase inhibitor. VL=viral load. *Six patients had more than one reason for ineligibility.
291 assigned ongoing
triple therapy
291 received allocated treatment
291 included in intention-
to-treat analysis
296 included in intention-
to-treat analysis
1 died before end-of-trial
follow-up
11 withdrew or lost to follow-up
296 assigned PI
monotherapy
290 received allocated treatment
587 randomised
695 patients assessed for eligibility
6 died before end-of-trial
follow-up
5 withdrew or lost to follow-up
6 did not receive PI monotherapy
4 patient decision
2 developed adverse event
after switch from NNRTI to
PI and never stopped NRTIs
108 ineligible*
30 previous ART change due to
unsatisfactory VL response
28 VL 50 copies per mL or higher at screening
or previous 24 weeks
19 did not return after screening
8 not on two NRTIs and one NNRTI or
PI regimen
29 other reasons
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routine follow-up, but if higher (ie, on the third 
consecutive test), this result met the protocol deﬁ nition 
of conﬁ rmed rebound and so the patient was required to 
change treatment, and we did a repeat test 4 weeks later.
We did genotypic resistance testing on all viral load 
rebound samples that were conﬁ rmed or preceded 
treatment switch. We did genotypic testing at site 
laboratories, repeated at the central laboratory if local 
sequencing was unsuccessful. We used the Stanford 
algorithm for drug susceptibility prediction. If we 
identiﬁ ed resistance mutations, we compared them with 
any genotypic testing reports from before the trial.
Outcomes
The primary outcome was loss of future drug options, 
deﬁ ned as new intermediate-level or high-level resistance 
to one or more drugs in contemporary use to which we 
deemed patient’s virus to be sensitive at trial entry 
(assessed at 3 years). We deﬁ ned contemporary use on 
the basis of inclusion in present UK treatment guidelines,1 
with saquinavir added because this drug was taken by 
some participants during the trial.
Secondary outcomes were occurrence of serious 
drug-related or disease-related complications, including 
death or serious AIDS-deﬁ ning (excluding oesophageal 
candidiasis or chronic mucocutaneous herpes simplex 
virus infection) or non-AIDS-deﬁ ning illness; total number 
of grade 3 and 4 adverse events; conﬁ rmed virological 
rebound; CD4 cell count change from baseline; neuro-
cognitive function change from baseline; cardiovascular 
risk change from baseline; and health-related quality of life 
change from baseline (mental and physical health sum-
mary scores). Additional speciﬁ ed safety outcomes were 
facial lipoatrophy, abdominal fat accumulation, peripheral 
neuropathy, and estimated glomerular ﬁ ltration rate.
Statistical analysis
We deﬁ ned non-inferiority of the PI-mono group by the 
upper limit of the two-sided 95% CI for the diﬀ erence in 
proportions of patients who maintain all future drug 
options during 3 years (OT group minus the PI-mono 
group) being less than 10%. We chose the 10% 
non-inferiority margin on the basis of US Food and Drug 
Administration guidance 23,24 and with reference to other 
protease inhibitor monotherapy trials.9 Using a survival 
analysis approach (on a hazard ratio scale) to allow 
inclusion of all follow-up data for estimation of the 
primary endpoint, and assuming that 97% of patients in 
the OT group would meet the primary endpoint,7,25,26 with 
an 85% power and a 10% loss to follow-up, we estimated 
that about 280 patients per group would be needed to 
show non-inferiority. This approach gives a conservative 
estimate of the sample size, which has the additional 
advantage of allowing precise estimates of important 
secondary safety outcomes. On the basis of a conventional 
analysis of proportions, the power of the study to show 
non-inferiority for the primary endpoint with use of the 
same parameters would be more than 99%.
All comparisons were as randomised (intention to 
treat). We deemed a per-protocol analysis not relevant 
for this pragmatic trial in view of the fact that a switch 
OT (n=291) PI-mono (n=296) Total (n=587)
Demographic and clinical characteristics
Age (years) 43 (37–49, 23–75) 45 (39–50, 23–67) 44 (38–49, 23–75)
Route of infection
Homosexual 175 (60%) 176 (59%) 351 (60%)
Heterosexual 108 (37%) 108 (36%) 216 (37%)
Other 8 (3%) 12 (4%) 20 (3%)
Female 64 (22%) 73 (25%) 137 (23%)
Ethnic origin
White 206 (71%) 195 (66%) 401 (68%)
Black 73 (25%) 90 (30%) 163 (28%)
Other 12 (4%) 11 (4%) 23 (4%)
Hepatitis C virus antibody positive 7 (2%) 14 (5%) 21 (4%)
HIV disease status
Previous AIDS-deﬁ ning illness 59 (20%) 57 (19%) 116 (20%)
Nadir CD4 count (cells per μL) 181 (90–258) 170 (80–239) 178 (86–250)
Baseline CD4 count (cells per μL) 512 (386–658) 516 (402–713) 513 (392–682)
Undetectable baseline HIV viral load 276 (95%) 279 (94%) 555 (95%)
Duration of undetectable viral load 
(months)
36 (17–62) 38 (22–66) 37 (20–63)
ART history
Years since ART started 3·9 (2·0–6·4) 4·2 (2·4–6·9) 4·0 (2·2–6·7)
On ﬁ rst ART combination 91 (31%) 96 (32%) 187 (32%)
Number of drugs ever received 5 (3–6) 4 (3–6) 4 (3–6)
NNRTI at entry
Any 157 (54%) 157 (53%) 314 (53%)
Efavirenz 115 (40%) 115 (39%) 230 (39%)
Nevirapine 42 (14%) 39 (13%) 81 (14%)
Etravirine 0 3 (1%) 3 (1%)
Protease inhibitor at entry
Any 134 (46%) 139 (47%) 273 (47%)
Atazanavir 59 (20%) 59 (20%) 118 (20%)
Lopinavir 28 (10%) 49 (17%) 77 (13%)
Darunavir 24 (8%) 13 (4%) 37 (6%)
Saquinavir 16 (5%) 15 (5%) 31 (5%)
Fosamprenavir 7 (2%) 3 (1%) 10 (2%)
NRTIs at entry
Any 291 (100%) 296 (100%) 587 (100%)
Emtricitabine and tenofovir 190 (65%) 180 (61%) 370 (63%)
Lamivudine and abacavir 80 (27%) 82 (28%) 162 (28%)
Other 21 (7%) 34 (11%) 55 (9%)
Resistance
Resistance test result available before trial 181 (62%) 165 (56%) 346 (59%)
Intermediate-level or high-level resistance 
to NRTI or NNRTI before trial* 
4 (2%) 7 (4%) 11 (3%)
Data are median (IQR, range), median (IQR), or n (%). OT=ongoing triple therapy. PI-mono=protease inhibitor 
monotherapy. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside 
reverse transcriptase inhibitor. *Percentages are of the numbers of patients with resistance test results available before 
the trial.
Table 1: Baseline characteristics 
For the Stanford University 
HIV Drug Resistance Database
see http://hivdb.stanford.edu
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back to combination treatment in the PI-mono group 
was an intrinsic element of the clinical strategy being 
assessed. Statistical tests are two-sided and test the 
hypotheses of no diﬀ erence between randomised 
groups. We estimated the absolute diﬀ erence between 
groups in reduction of future drug options using 
Kaplan-Meier analysis, with the 95% CI (two-sided) 
derived with bootstrap methods. In this analysis and 
other time-to-event analyses, we censored participants at 
the time of death, loss to follow-up, or withdrawal. The 
primary analysis included all new resistance mutations 
noted that conferred intermediate-level or high-level 
drug resistance. We predeﬁ ned a sensitivity analysis in 
which we restricted loss of drug options to classes to 
which the patient was exposed during the trial, thus 
excluding mutations that were probably archived 
(ie, acquired at transmission or during treatment before 
enrolment, but unknown at trial entry).
For secondary endpoints, we compared binary outcome 
variables between groups using χ² or Fisher’s exact tests, 
with conventional or Agresti-Caﬀ o 95% CIs for the risk 
diﬀ erence and logistic regression models for adjusted 
analyses. For continuous variables, we compared groups 
by use of mean change from baseline and t tests or linear 
regression; we estimated change from baseline to the last 
available visit at which a measurement was done at or 
after week 144 (we did not include patients without such 
data). We estimated the proportion of patients who had 
viral load rebound with Kaplan-Meier analysis and 
compared groups by use of a log-rank test. We compared 
incidence rates with Poisson regression. We compared 
adherence during the entire follow-up period between 
groups with generalised estimating equations (in-
dependent correlation structure; binomial distribution).
We used Stata version 12.1 for all analyses. A data 
monitoring committee reviewed interim data annually. 
This trial is registered with the International Standard 
Randomised Controlled Trial Number registry, number 
ISRCTN04857074.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Nov 4, 2008, and July 28, 2010, we randomly 
allocated 587 participants to OT (291) or PI-mono 
(296; ﬁ gure 1). One (<1%) died and 11 (4%) withdrew or 
were lost to follow-up in the OT group, whereas six (2%) 
died and ﬁ ve (2%) withdrew or were lost to follow-up in 
the PI-mono group. Study visits ended on Nov 1, 2013. 
The median duration of trial follow-up was 44 months 
(maximum 59 months). Participant characteristics were 
similar between groups (table 1). 
In the PI-mono group, initial drug choices were 
darunavir in 233 (80%) of patients, lopinavir in 40 (14%), 
atazanavir in 16 (6%), and saquinavir in 1 (<1%); 58% were 
still taking monotherapy at trial end. Combination 
treatment was reintroduced for the following reasons: 
69 (23%) for protocol-deﬁ ned conﬁ rmed viral rebound 
(appendix p 8), 11 (4%) for viral rebound not meeting 
protocol criteria, 16 (5%) for toxic eﬀ ects, and 22 (7%) 
for other or unknown reasons; 6 (2%) never started 
monotherapy. Overall, 72% of follow-up time was spent 
on monotherapy. Self-reported adherence to study drugs 
was high: participants reported not missing any ART 
doses in the past 2 weeks at 4301 (93%) of 4635 visits in 
the OT group and 4376 (92%) of 4748 visits in the PI-mono 
group (p=0·52).
The number of patients with loss of future drug options 
at 3 years (the primary outcome) was two patients 
(Kaplan-Meier estimate 0·7%) in the OT group and 
six (2·1%) in the PI-mono group (diﬀ erence 1·4% 
[95% CI –0·4 to 3·4]), therefore meeting the non-
inferiority criterion. PI-mono was also non-inferior with 
prespeciﬁ ed analyses of loss of future drug options 
during the full trial follow-up period (OT 1·8%; PI-mono 
2·1%; diﬀ erence 0·2% [–2·5% to 2·6]) and loss of future 
drug options during the full trial period but excluding 
mutations that were probably archived (OT 1·5%; 
PI-mono 1·0%; diﬀ erence –0·4% [–2·9% to 1·4%]). One 
(<1%) participant on atazanavir monotherapy developed 
the Ile50Leu mutation (as a mixture with wild-type), 
conferring predicted high-level atazanavir resistance. We 
detected an isolated Leu90Met mutation in two (<1%) 
patients on darunavir monotherapy; both resuppressed 
Drugs received 
during trial
Reverse transcriptase 
mutations
Protease mutations Lost drug options
OT
1* ABC, 3TC, ATV Val118Ile, Val179Asp, 
Met184Val
Ile84Val 3TC, FTC, ATV, SQV, 
FPV, TPV
2 TDF, FTC, RPV, 
DRV
Leu100Ile, Lys103Asn, 
Met184Val
Ala71Val 3TC, FTC, NVP, EFV, ETV, 
RPV
3 TDF, FTC, ETV, 
NVP, EFV, DRV
Lys65Arg, Glu138Ala, 
Tyr181Cys, Met184Val/Ile, 
His221Tyr, Met230Leu
·· 3TC, FTC, ABC, TDF, 
NVP, EFV, ETV, RPV
4* TDF, FTC, DRV Val106Ala ·· NVP,‡ EFV‡
PI-mono
5* ATV ·· Lys20Thr, Ile50Leu/Ile, 
Ala71Thr
ATV
6* DRV ·· Leu90Met SQV†
7* DRV ·· Ala71Thr, Leu90Met SQV†
8* DRV Lys103Asn ·· NVP,‡ EFV‡
9* DRV Lys103Asn ·· NVP,‡ EFV‡
10* DRV Met41Leu, Thr215Asp ·· ZDV‡
OT=ongoing triple therapy. ABC=abacavir. 3TC=lamivudine. ATV=atazanavir. FTC=emtricitabine. SQV=saquinavir. 
FPV=fosamprenavir. TPV=tipranavir. TDF=tenofovir. RPV=rilpivirine. NVP=nevirapine. EFV= efavirenz. ETV=etravirine. 
DRV=darunavir. PI-mono=protease inhibitor monotherapy. ZDV=zidovudine. *Met primary outcome at 3 years. 
†Possibly archived resistance. ‡Probably archived resistance (excluded in sensitivity analysis).
Table 2: Individual patients with loss of future drug options by end of trial
See Online for appendix
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with reintroduction of NRTIs. This mutation, possibly 
archived, does not aﬀ ect darunavir sensitivity, but confers 
resistance to saquinavir and thus meets the endpoint 
deﬁ nition. Three (1%) patients in the PI-mono group had 
NRTI or NNRTI mutations detected, probably archived 
from previous treatment. In the OT group, three (1%) 
patients had loss of future drug options to drug classes 
that they were taking and one (<1%) taking a protease-
inhibitor-based regimen had NNRTI mutations that were 
probably archived (table 2; appendix p 2–3). 
We noted one or more episodes of conﬁ rmed viral load 
rebound in eight (Kaplan-Meier estimate 3·2%) patients in 
the OT group and 95 (35·0%) in the PI-mono group 
during all follow-up: absolute risk diﬀ erence 31·8% 
(95% CI 24·6–39·0; p<0·0001). Rebound while actually on 
monotherapy (occurred in 93 patients) was more common 
in the ﬁ rst year (24 per 100 person-years) than in subsequent 
years (six per 100 person-years; ﬁ gure 2). Findings were 
similar with use of an extended deﬁ nition of viral load 
rebound (appendix, p 9) and across the diﬀ erent protease 
inhibitors used as monotherapy. The median peak viral 
load at ﬁ rst episode of rebound on monotherapy was 
526 copies per mL (peak was less than 400 copies per mL 
in 39 [42%] of 93 patients); of the 91 (98%) patients with 
subsequent tests available, 22 (24%) had resuppressed 
spontaneously and 69 (76%) resuppressed after changing 
ART: 47 (68%) by adding NRTIs only, 18 (26%) by adding 
NRTIs and changing the protease inhibitor to an NNRTI, 
two (3%) by changing the protease inhibitor monotherapy 
drug, and two (3%) other changes (appendix p 8). Viral load 
was resuppressed to less than 50 copies per mL after a 
median of 3·5 weeks (ﬁ gure 2).
We noted no diﬀ erences in serious drug-related or 
disease-related complications (death, AIDS, or serious 
non-AIDS) between groups (table 3). Causes of the 
one death in the OT group and six in the PI-mono group 
were diverse, and we did not deem any to be related to 
treatment strategy (appendix p 4). CD4 cell count 
increased similarly in both groups (table 3). Serious 
adverse events and clinical grade 3 and 4 adverse events 
did not diﬀ er between groups (table 3, appendix p 5–7). 
Fewer patients in the PI-mono group had a serum 
phosphate concen tration of less than 0·65 mmol/L 
(p<0·0001, appendix p 6) and an eGFR of less than 
60 mL/min per 1·73 m² during follow-up (table 3). 
However, mean change in eGFR did not diﬀ er between 
groups (table 3), and only one case of end-stage renal 
failure occurred: a patient in the PI-mono group with 
pre-existing chronic renal impairment. Proportions of 
patients with symptomatic peripheral neuropathy, facial 
lipoatrophy, or abdominal fat accumulation during 
follow-up, and changes in neurocognitive function 
summary, cardiovascular disease risk, or quality of life 
summary scores did not diﬀ er between groups (table 3).
Discussion
In patients who have achieved viral load suppression 
with combination treatment, a maintenance strategy of 
protease inhibitor monotherapy, with reintroduction of 
combination treatment in the event of viral load rebound, 
was non-inferior to continuous combination treatment 
for preservation of future treatment options during 
3–5 years. Furthermore, and perhaps more relevant than 
is non-inferiority for understanding of the clinical 
implications of this approach, the ﬁ ndings showed that 
the absolute number of patients who lost future drug 
options with protease inhibitor monotherapy was very 
low. Only one patient developed clinically signiﬁ cant 
resistance to a protease inhibitor taken as monotherapy, 
an Ile50Leu mutation with atazanavir monotherapy; 
clinical negative eﬀ ects are mitigated by an increase in 
sensitivity to other protease inhibitors conferred by this 
mutation.27 None of the 277 patients taking darunavir or 
lopinavir (the recommended options for monotherapy in 
this trial, taken by almost all patients) developed 
resistance aﬀ ecting their eﬃ  cacy. The very low amount of 
Figure 2: Viral load rebound and resuppression
(A) Time to viral rebound. (B) Time to viral resuppression after change of ART in the PI-mono group. The time to 
ﬁ rst viral load of less than 50 copies per mL (midpoint between last test 50 copies per mL or more and ﬁ rst test of 
less than 50 copies per mL) for patients at the time of ﬁ rst rebound who were taking protease inhibitor 
monotherapy (excluding two patients in the PI-mono group who rebounded while not on monotherapy) is shown. 
Outcomes by type of treatment switch are shown in the appendix (p 8). ART=antiretroviral therapy. HR=hazard 
ratio. OT=ongoing triple therapy. PI-mono=protease inhibitor monotherapy. VL=viral load. 
HR 13·9; 95% CI 6·8–28·6; p<0·0001
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resistance concurs with previous trials of monotherapy 
(and trials with protease-inhibitor-based combinations),5–9 
but extend ﬁ ndings from these trials to provide the 
crucial long-term randomised outcome data from a large 
pragmatic trial needed to provide conﬁ dence in use of 
protease inhibitor monotherapy in clinical practice.
We sought resistance fastidiously, testing conﬁ rmed 
viral rebound samples irrespective of level of viraemia 
with standard population sequence genotypic testing. 
Although protease inhibitor resistance could occur in 
other regions of the virus, such as gag or env genes, or in 
minority species that are not detected by population 
assays,3 previous minority species sequencing in patients 
with viral rebound on monotherapy has shown only a 
small excess of resistance compared with that detected by 
population sequencing.28,29 Furthermore, our ﬁ nding that 
patients with viral load rebound in the PI-mono group, 
without exception, achieved full viral load suppression 
when switched to combination treatment (usually by 
reintroduction of NRTIs) provides an important 
assurance that any mutations that were not detected by 
population sequencing did not aﬀ ect subsequent 
treatment eﬃ  cacy. The follow-up period of 3–5 years, 
long for an HIV treatment trial, is suﬃ  cient to have 
conﬁ dence that preservation of treatment options is 
likely to be durable in the long term.
A higher proportion of patients in the PI-mono group 
had viral rebound, as expected, although the diﬀ erence 
was much greater than the 10–13% noted in a previous 
systematic review.9 Viral suppression is the traditional 
outcome variable for comparison of treatment regimens 
in clinical trials, but is less informative in long-term 
strategy trials such as this one, especially in view of the 
diﬀ erent eﬀ ect of viral rebound on risk of drug resistance 
for diﬀ erent drug classes. Aside from risk of resistance 
(shown to be negligible in this study), these brief episodes 
of low-level viraemia, rapidly reversed by reintroduction 
of combination treatment, are unlikely to have adverse 
long-term clinical eﬀ ects: much higher levels of viraemia 
are needed than those noted in this study to drive HIV 
disease progression,30 and CD4 cell count increases and 
total HIV disease-related clinical events were similar 
between the two groups. Risk of transmission to others 
arising from such short episodes of low-level viraemia is 
also likely to be negligible in view of the fact that 
transmission is exceedingly rare in patients with a low 
viral load, whether on or oﬀ  ART.31,32 Although more 
deaths occurred in the PI-mono group, the diﬀ erence was 
not statistically signiﬁ cant and the causes were diverse, 
without a plausible link to the drugs taken or HIV disease 
progression. This ﬁ nding is probably a chance imbalance, 
and follow-up of the cohort continues. Further analyses of 
OT (n=291) PI-mono (n=296) Diﬀ erence (95% CI)* p value
Serious drug-related or disease-related complications
Total 8 (2·7%) 15 (5·1%) 2·3% (–0·8 to 5·4) 0·15
Death† 1 (0·3%) 6 (2·0%) 1·7% (–0·3 to 3·6) 0·12
AIDS-deﬁ ning event 1 (0·3%) 1 (0·3%) 0·0% (–1·3 to 1·3) 1·00
Serious non-AIDS event 7 (2·4%) 12 (4·1%) 1·6% (–1·2 to 4·5) 0·26
CD4 change (cells per mm³) 93 (10) 109 (9) 16 (–11 to 42) 0·30
Serious adverse event 45 (15·5%) 56 (18·9%) 3·5% (–2·6 to 9·6) 0·27
Total grade 3 or 4 adverse event 159 (54·6%) 137 (46·3%) –8·4% (–16·4 to –0·3) 0·043
Clinical grade 3 or 4 adverse event 49 (16·8%) 65 (22·0%) 5·1% (–1·3 to 11·5) 0·12
EGFR
<60 mL/min per 1·73 m²‡ 28/290 (9·7%) 15/296 (5·1%) –4·6% (–8·8 to –0·4) 0·033
Change (mL/min per 1·73 m²) –5·13 (0·67) –3·83 (0·66) 1·30% (–0·55 to 3·15) 0·092
Symptomatic peripheral neuropathy§ 44/283 (15·5%) 46/289 (15·9%) 0·4% (–5·6 to 6·3) 0·90
Facial lipoatrophy¶ 23/282 (8·2%) 35/289 (12·1%) 4·0% (–1·0 to 8·9) 0·12
Abdominal fat accumulation¶ 47/274 (17·2%) 57/277 (20·6%) 3·4% (–3·1 to 10·0) 0·30
10 year cardiovascular disease risk change 1·32 (0·31) 1·59 (0·31) 0·27 (–0·58 to 1·12) 0·52
Neurocognitive function change (NPZ-5 score) 0·53 (0·04) 0·52 (0·04) –0·01 (–0·11 to 0·09) 0·94
Quality of life change
Mental health score –0·75 (0·57) –1·82 (0·54) –1·07 (–2·61 to 0·47) 0·17
Physical health score –0·76 (0·53) –1·17 (0·46) –0·41 (–1·79 to 0·98) 0·56
Data are n (%), n/N (%), or mean (SE). Means are predicted means adjusted for baseline values. The numbers of patients are the numbers of patients having the speciﬁ ed event 
during the entire trial follow-up period. OT=ongoing triple therapy. PI-mono=protease inhibitor monotherapy. EGFR=estimated glomerular ﬁ ltration rate. *Diﬀ erence between 
PI-mono and OT. Absolute diﬀ erences for binary outcomes or mean diﬀ erences for continuous outcomes shown. †Causes of death were metastatic adenocarcinoma in the 
OT group and suicide, pulmonary embolism, breast carcinoma (recurrent), small-cell lung carcinoma, glioblastoma, and anal carcinoma in the PI-mono group (details in appendix 
p 4). ‡New episodes after baseline. §Symptomatic peripheral neuropathy at one or more of the post-baseline-scheduled follow-up assessments (irrespective of status at baseline). 
¶Facial lipoatrophy present at one or more of the post-baseline-scheduled follow-up assessments (irrespective of status at baseline), assessed by a doctor or nurse; abdominal fat 
accumulation at last available assessment compared with baseline (irrespective of status at baseline), self-assessed by the patient.
Table 3: Secondary outcomes
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predictive factors are planned that might enable 
identiﬁ cation of patients at low risk of rebound. However, 
selection factors are unlikely to be able to remove the 
excess risk entirely, and rebound and resuppression 
should be viewed as an integral part of the strategy for 
some patients. After the ﬁ rst year of suppression on 
monotherapy, the risk of rebound is much reduced, and 
this factor might increase acceptability for patients.
We noted fewer episodes of renal impairment in the 
PI-mono group as expected in view of the well-recognised 
renal toxic eﬀ ects of NRTIs (especially tenofovir). 
However, the risk of serious drug toxic eﬀ ects can 
be minimised by close laboratory monitoring and 
pre-emptive treatment changes, and no patients in the 
OT group developed end-stage renal disease.33 This 
pragmatic trial in which clinicians were allowed to switch 
drugs at clinical discretion (rather than being restricted to 
single-protocol-mandated regimens) provides a realistic 
estimate of the eﬀ ect of protease inhibitor monotherapy 
in routine clinical practice, suggesting that beneﬁ ts in 
terms of renal toxic eﬀ ects would be small. We did not 
ﬁ nd any other clinical advantages of the monotherapy 
strategy. Treatment costs might be reduced, partly oﬀ set 
by increased monitoring costs, but considerations are 
complex, and detailed cost-eﬀ ectiveness analyses will be 
reported in a separate paper.
A concern with protease inhibitor monotherapy is that 
suboptimum drug penetration into the CNS might lead 
to harm.34,35 However, we noted no diﬀ erence in 
neurocognitive function between groups, nor any 
signiﬁ cant excess of neurological events in the PI-mono 
group. We used a small battery of neurocognitive tests 
(for feasibility in view of the large numbers of patients 
and repeated assessments), possibly less sensitive than a 
comprehensive neurocognitive assessment would be. 
Although we cannot rule out delayed eﬀ ects on neuro-
cognitive function or neurological events after longer 
periods on monotherapy than those in this study, the size 
and duration of our trial nevertheless provides reassur-
ance that even if monotherapy were to have less brain 
penetration, this factor is unlikely to have important 
clinical negative eﬀ ects.
The strengths of this trial are its size and duration 
(more than three times the randomly allocated person 
follow-up time of previous studies, allowing precise 
estimates of important but uncommon eﬃ  cacy and safety 
outcomes); low withdrawal and loss-to-follow-up; 
pragmatic design set in routine clinical care, with 
ﬂ exibility in drug selection in both treatment groups; and 
use of a primary eﬃ  cacy endpoint relevant to long-term 
management. The open-label design, a possible limi-
tation, is unlikely to have aﬀ ected detection of viral 
rebound or resistance (and hence the primary endpoint) 
because the protocol-mandated frequency of viral load 
testing was identical in the two groups (apart from 
two extra tests at weeks 4 and 8 in the monotherapy 
group), and we did resistance testing in everyone with 
viral rebound. Likewise, the open-label design is unlikely 
to have aﬀ ected adverse event detection because the 
frequency of laboratory safety monitoring was stand-
ardised and adverse events were graded with standardised 
diagnostic criteria. Another possible limitation is the 
absence of before-treatment resistance tests that would 
help rule out resistance acquired before the trial. 
Although entry criteria were broad, patients entering this 
trial were established for years on a stable eﬀ ective 
regimen, yet needed to be willing to change to an 
alternative regimen (in some cases adding new drugs 
with risk of side-eﬀ ects or increased pill burden) if 
randomly allocated to do so. In view of the absence of any 
certainty of beneﬁ t, only a few eligible patients would 
therefore have been likely to be prepared to participate. 
Such motivated patients might have better outcomes 
(perhaps mediated by adherence) than the general clinic 
population would have, and this notion is consistent with 
the very low amount of rebound and resistance noted in 
the OT group. The main study ﬁ nding that, despite 
high levels of viral load rebound, protease inhibitor 
monotherapy does not jeopardise future treatment 
options is likely to be generalisable internationally to 
settings where treatment is individualised and regular 
viral load monitoring done. However, protease inhibitor 
monotherapy is not appropriate for resource-limited 
settings delivering treatment without regular viral load 
monitoring.36
Protease inhibitor monotherapy is an acceptable 
alternative to standard combination ART for long-term 
HIV management, with a slight beneﬁ t in terms of a 
reduction of renal toxic eﬀ ects. The need for regular viral 
load monitoring and a possible switch back to combination 
treatment might be perceived as drawbacks, but this 
approach could nevertheless appeal to patients who are 
stable on treatment but wish to minimise their exposure 
to speciﬁ c drugs or more than one drug class. Broadly, the 
trial challenges the notion that combination treatment is 
essential for management of chronic HIV infection.
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